The study whether Sacubitril/Valsartan increase ultrafiltration and preserve residual kidney function in patients who are under peritoneral dialysis treatment.

JRCT ID: jRCT1031230413

Registered date:19/10/2023

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Chronic kidney failure during peritoneal dialysis therapy
• Date of first enrollment: 30/11/2022
• Target sample size: 35
• Study type: Observational

Outcome(s)

• Primary Outcome: Extracellular fluid volume by impedance method, daily water removal volume, daily urine volume, and daily sodium excretion
• Secondary Outcome: Edema, body weight, blood pressure, cardiothoracic ratio, serum creatinine, serum electrolytes, blood gases, PET, weekly Kt/V, weekly CCr, hANP, blood beta-2 microglobulin, cardiac function by echocardiography, flow mediated dilation measurement

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

1) Patients who obtained wrriten consent of participation in this research from patients or proxies.
2) Patinets who have hypertension or heart failure.
3) Patinets who underwent PET examination (PET, Weekly CCr, Weekly Kt/V, Daily urine volume mesurement) at least once.

Exclude criteria

1) Patients who take any angiotensin-converting-enzyme inhibitors within 36 hours of the start of the study.
2) Patients who have had side effects in the past with the drug or its ingredients (valsartan and/or neprilysin).

Related Information

• Primary Sponsor: Yoshino Atsunori
• Secondary Sponsor: Takeda Tetsuro